TG Therapeutics (TGTX) Tops Q2 EPS by 9c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $73.47 million versus the consensus estimate of $65.89 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Blue Moon Metals cleared to build at Nevada tungsten project
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth